These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16009445)

  • 21. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
    Carmona MC; Louche K; Nibbelink M; Prunet B; Bross A; Desbazeille M; Dacquet C; Renard P; Casteilla L; Pénicaud L
    Int J Obes (Lond); 2005 Jul; 29(7):864-71. PubMed ID: 15917863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
    Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
    J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
    Srivastava RA
    Eur J Pharmacol; 2009 Apr; 607(1-3):258-63. PubMed ID: 19245804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
    Freed MI; Ratner R; Marcovina SM; Kreider MM; Biswas N; Cohen BR; Brunzell JD;
    Am J Cardiol; 2002 Nov; 90(9):947-52. PubMed ID: 12398960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
    Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
    PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
    Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
    J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus.
    Atamer Y; Atamer A; Can AS; Hekimoğlu A; Ilhan N; Yenice N; Koçyiğit Y
    Braz J Med Biol Res; 2013 Jun; 46(6):528-32. PubMed ID: 23802228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
    Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
    Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
    Normén L; Frohlich J; Montaner J; Harris M; Elliott T; Bondy G
    Diabetes Care; 2004 Sep; 27(9):2241-2. PubMed ID: 15333491
    [No Abstract]   [Full Text] [Related]  

  • 40. The long-term effects of rosiglitazone on serum lipid concentrations and body weight.
    Shim WS; Do MY; Kim SK; Kim HJ; Hur KY; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):453-9. PubMed ID: 16984237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.